公开(公告)号：KR101631243B1

公开(公告)日：2016-06-17

申请号：KR1020090041567

申请日：2009-05-13

Applicant: 신일제약주식회사

Inventor： 이정민 ,  박재원 ,  성하창 ,  고성진 ,  김세나 ,  김선우 ,  조정원 ,  유성균

IPC: A61K8/97 ,  A61Q19/08

Abstract: 본발명은특정배합비율로구성된알렌드로네이트/키토산수용액과폴리메타크릴레이트/부탄올용액및 폴리비닐알콜/염화나트륨수용액을사용하여 W/O/W형에멀젼을간단한공정으로제조할수 있게함으로써, 알렌드로네이트의낮은생체이용률과위장관내 흡수율저하등의문제점을개선시킬수 있는새로운알렌드로네이트제제를제공할수 있게한 것이다.

公开(公告)号：KR1020100138352A

公开(公告)日：2010-12-31

申请号：KR1020090056856

申请日：2009-06-25

Applicant: 신일제약주식회사

Inventor： 이정민 ,  박재원 ,  이경은 ,  김선우 ,  성하창 ,  김세나

IPC: A61K47/34 ,  A61P19/10 ,  A61K31/66

CPC classification number: A61K47/34 ,  A61K31/66

Abstract: PURPOSE: A pharmaceutical composition containing alendronate and polyethylene glycol is provided to improve drug penetration rate. CONSTITUTION: A pharmaceutical composition for preventing and treating bone diseases contains 0.5-5 weight% of alendronate, 65-95 weight% of polyethylene glycol, and 2.5-30 weight% of steraroyl macrogolglyceride. The composition further contains 1.5-15 weight% of surfactant, 0.1-30 weight% of distilled water and 0.4-3 weight% of sodium chloride. A pharmaceutical composition is prepared by mixing alendronate, polyethylene glycol and steraroyl macrogolglyceride and dissolving at 80-100 °C.

Abstract translation: 目的：提供含有阿仑膦酸钠和聚乙二醇的药物组合物，以提高药物的渗透率。 构成：用于预防和治疗骨疾病的药物组合物含有0.5-5重量％的阿仑膦酸盐，65-95重量％的聚乙二醇和2.5-30重量％的硬脂酰聚甘油三酯。 该组合物还含有1.5-15重量％的表面活性剂，0.1-30重量％的蒸馏水和0.4-3重量％的氯化钠。 药物组合物通过将阿仑膦酸钠，聚乙二醇和硬脂酰聚甘油甘油酯混合并在80-100℃下溶解来制备。

公开(公告)号：KR1020100122589A

公开(公告)日：2010-11-23

申请号：KR1020090041567

申请日：2009-05-13

Applicant: 신일제약주식회사

Inventor： 이정민 ,  박재원 ,  성하창 ,  고성진 ,  김세나 ,  김선우 ,  조정원 ,  유성균

IPC: A61K8/97 ,  A61Q19/08

CPC classification number: A61K8/97 ,  A61K2800/522 ,  A61K2800/85 ,  A61Q19/08

Abstract: PURPOSE: A method for manufacturing a novel alendronate emulsion dry is provided to produce W/O/W type emulsion by simple process. CONSTITUTION: A method for manufacturing a novel alendronate emulsion dry comprises: a step of adding a solution containing 0.05-5 weight parts of alendronate and 0.05-5 weight parts of chitosan dissolved in 5-100 weight parts of water in a butanol solution in a volume ratio of 2:1-3:1 to prepare W/O type emulsion; a step of adding W/O type emulsion to a solution containing 0.5-2%(w/v) of polyvinyl alcohol solution and 0.7-1%(w/v) sodium chloride solution in a volume ratio of 2:1-10:3 to prepare W/O/W type emulsion; a step of compressing or concentrating the emulsion to remove butanol; a step of adding a solution containing 0.5-20%(w/v) of saccharide selected from a group consisting of mannitol, lactose and glucose in a volume ratio of 2:1-5:1; and a step of drying. A pharmaceutical composition for preventing and treating bone diseases contains alendronate emulsion dry as an active ingredient.

Abstract translation: 目的：提供一种制备新型阿仑膦酸盐乳液干燥的方法，通过简单的工艺生产W / O / W型乳液。 构成：制备新型阿伦膦酸酯乳液的方法包括：将溶于5-100重量份水中的0.05-5重量份阿仑膦酸盐和0.05-5重量份壳聚糖的溶液加入到丁醇溶液中的步骤 体积比为2：1-3：1，制备W / O型乳液; 将含有0.5-2％（w / v）聚乙烯醇溶液和0.7-1％（w / v）氯化钠溶液的溶液以体积比为2：1-10：1的溶液加入W / O型乳液的步骤： 3制备W / O / W型乳液; 压缩或浓缩乳液以除去丁醇的步骤; 添加体积比为2：1-5：1的含有选自甘露糖醇，乳糖和葡萄糖的0.5-20％（w / v）糖的溶液的溶液的步骤; 和干燥步骤。 用于预防和治疗骨疾病的药物组合物含有作为活性成分的阿仑膦酸盐乳液。